Combined treatment of voiding disorders in women with m-cholinolytic and alpha 1-adrenoblocker
- Authors: Danilov VV1, Volnykh IY.1, Abdullaeva SK1, Danilova TI1
-
Affiliations:
- Issue: No 3 (2004)
- Pages: 49-53
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/275317
- ID: 275317
Cite item
Full Text
Abstract
The drug spasmex (trospium chloride) having an m-cholinolytic
and myotropic spasmolytic action has been used for treatment of enuresis
in women with imperative voiding syndrome. Spasmex was given
in combination with alpha 1-adrenoblockers to 20 women. The clinical
picture was assessed with the original table. Urodynamic alterations
were registered by means of home uroflowmeter. Clinical parameters
improved 2 times after 4 weeks of the treatment. Mean effective
capacity of the urinary bladder increased by 25%. Spasmex in
combination with terasozine was well tolerated and had no side effects.
and myotropic spasmolytic action has been used for treatment of enuresis
in women with imperative voiding syndrome. Spasmex was given
in combination with alpha 1-adrenoblockers to 20 women. The clinical
picture was assessed with the original table. Urodynamic alterations
were registered by means of home uroflowmeter. Clinical parameters
improved 2 times after 4 weeks of the treatment. Mean effective
capacity of the urinary bladder increased by 25%. Spasmex in
combination with terasozine was well tolerated and had no side effects.
References
- Мазо Е. Б., Кривобородов Г. Г. Гиперактивный мочевой пузырь. Consilium medicum 2003; 5 (7): 405-411.
- Пушкарь Д. Ю. Гиперактивный мочевой пузырь у женщин. М.: МедПрессИнформ.; 2003.
- Steers W. D. Overactive Bladder (OAB): What we thought we knew and what we know today. EAU J. Urol. 2002; 1 (4): 3-10.
- Mundy A. R., Stephenson T. P. In: Mundy A. R., Stephenson T. P., Wein A. J., eds. Urodynamics: principles, practice and application. Edinburgh; 1984; chapt. 21: 212-228.
- Пушкарь Д. Ю., Щавелева О. Б. Спазмекс в лечении больных с гиперактивным мочевым пузырем. Урология 2003; 4: 46-49.
- Chancellor M., Blaivas J. С. In: Practical neurology. Genitourinary complications in neurologic disease. Boston; 1995. 285- 290.
- Данилов В. В., Вольных И. Ю. Некоторые аспекты клинической оценки форм недержания мочи у женщин. В кн.: Материалы III Дальневосточной региональной конф. "Избранные вопросы урологии и андрологии. Диагностика и лечение". Владивосток; 2003. 176-186.
- Pietzko A., Dimpfel W., Shwantes U. et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur. J. Clin. Pharmacol. 1994; 47: 337-343.
- Madersbacher H., Stohrer M., Richter R. et al. Trospium chloride versus oxybutynin: a randomyzed double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Br. J. Urol. 1995; 75 (4): 452-456.
- Halaska M., Ralph G., Wiedemann. A. Controlled, doubleblind, multicentre clinical trial to investigate long-term tolerabity and efficacy of trospium chloride in patients with detrusor instability. Wld J. Urol. 2003; 20 (6): 392-399
Supplementary files
